Funding and Support

Current funding for Cochrane Gut

Previous funding

Cochrane Gut was formed in June 2020 by the merger of Cochrane Gastrointestinal and Pancreatic Diseases and Cochrane IBD. The previous sources of funding for these groups were:

Cochrane Gastrointestinal and Pancreatic Diseases

  • Astra (Exploratory Meeting, October 1996), UK
  • AstraZeneca (Systematic Reviews Workshop on H. pylori eradication, June 1999), UK
  • AstraZeneca (Systematic review of NSAID GI complications*, December 2009), Canada
  • Canadian Institutes of Health Research, Canada
  • Glaxo Wellcome (Exploratory Meeting, October 1996), UK
  • McMaster University, Canada
  • NHS HTA Programme (Systematic Reviews of Management of Non-Ulcer Dyspepsia), UK
  • NHS Research and Development Programme (Core Support), UK
  • Oxfordshire Health Authority Charitable Fund (Systematic Review), UK
  • University of Leeds, UK

*AstraZenexa commissioned a systematic review, undertaken by the UGPD group editorial staff. Funding was solely provided to conduct the review. AstraZeneca provided no other funding or support to the UGPD group.

Cochrane IBD

  • Crohn's and Colitis Canada
  • CIHR Knowledge Translation Branch (CON - 105529)
  • CIHR Institutes of Nutrition, Metabolism and Diabetes (INMD)
  • Infection and Immunity (III)
  • Ontario Ministry of Health and Long Term Care (HLTC3968FL-210-2235)